69 completed, 31 terminated, 17 unknown, 15 recruiting. 150 Phase 3, 34 Phase 2.
Follow Hemoglobinopathies: new trials by email Literature Review of Hemoglobinopathies trials Research Report on Hemoglobinopathies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/ βC Genotype Exa-cel - Sickle Cell Disease | Phase 3 | Withdrawn | Vertex Pharmaceuticals Incorporated | 2027-07-31 | 2026-03-25 | |
| Glutamine Early Start in Children With SCD Younger Than Five Glutamine, Standard of Care (SOC) - Sickle Cell Disease (SCD) | Phase 3 | Not yet recruiting | Ain Shams University | 70 | 2026-12-01 | 2026-11-17 |
| Combination Therapy With Danazol, Prednisolone, and Thalidomide for Thalidomide-Refractory Transfusion-Dependent β-Thalassemia Thalidomide, Danazol, Prednisolone - Beta-Thalassemia, Thalassemia | Phase 3 | Recruiting | Khyber Medical University Peshawar | 172 | 2026-10-12 | 2026-10-21 |
| Evaluation of the Efficacy of Iloprost in the Management of Vaso-occlusive Crises in Adult Patients With Sickle Cell Disease Iloprost, Placebo - Vaso-Occlusive Crises, Sickle Cell Disease | Phase 3 | Not yet recruiting | University Hospital, Rouen | 144 | 2026-09-01 | 2026-03-27 |
| A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD) Mitapivat Matched Placebo, Mitapivat - Sickle Cell Disease | Phase 3 | Recruiting | Agios Pharmaceuticals, Inc. | 159 | 2026-07-21 | 2026-10-28 |
| Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease Lidocain, Placebo, Standard of care - Vaso-Occlusive Pain Episode in Sickle Cell Disease | Phase 3 | Recruiting | Nantes University Hospital | 104 | 2026-07-03 | 2026-09-09 |
| Analgesic Effect of Parecoxib Versus Morphine in SCD Patients Presenting to the Emergency Department Parecoxib, Morphine - Sickle-Cell Disease with Crisis | Phase 3 | Not yet recruiting | Oman Medical Speciality Board | 226 | 2026-05-01 | 2025-03-20 |
| Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to Severe Sickle Cell Anemia Pharmacokinetic based dosage change, Pharmacokinetic dosing - Sickle Cell Disease (SCD) | Phase 2 / Phase 3 | Recruiting | Yves Pastore | 29 | 2026-02-03 | 2026-08-21 |
| Optimal Timing of Ketamine Initiation for SCD Pain Ketamine hydrochloride injection, Placebo - Sickle Cell Disease, Sickle Cell Crisis | Phase 3 | Not yet recruiting | Boston Children's Hospital | 90 | 2026-02-01 | 2026-03-09 |
| Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease PCV21, 20vPCV - Sickle Cell Disease | Phase 3 | Recruiting | Sanofi | 100 | 2026-01-20 | 2026-04-15 |
| Evaluating the Effect of N-Acetyl Cysteine and Alpha Lipoic Acid in Patients With Beta Thalassemia Iron chelating intervention, N Acetyl cysteine 600mg, Alpha Lipoic Acid 600 MG Oral Tablets - Beta Thalassemia | Phase 3 | Not yet recruiting | Tanta University | 66 | 2025-08-30 | 2025-09-05 |
| Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease Tocilizumab (RoActemra®, 20 mg/mL)., Placebo (NaCl 0.9%) - Sickle Cell Disease, Acute Chest Syndrome | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 130 | 2025-08-27 | 2026-06-24 |
| The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease Rilzabrutinib, Placebo - Sickle Cell Disease | Phase 3 | Recruiting | Sanofi | 192 | 2025-08-12 | 2026-11-18 |
| A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis L-citrulline, Placebo - Sickle Cell Disease | Phase 3 | Not yet recruiting | Asklepion Pharmaceuticals, LLC | 120 | 2025-07-25 | 2025-05-29 |
| A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease Etavopivat, Placebo - Sickle Cell Disease | Phase 3 | Recruiting | Novo Nordisk A/S | 510 | 2025-02-17 | 2026-09-17 |
| Zinc for Infection Prevention in Sickle Cell Anemia-2 (ZIPS-2) zinc sulfate, Placebo - Sickle Cell Disease | Phase 2 / Phase 3 | Completed | Indiana University | 100 | 2025-02-10 | 2026-01-30 |
| A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia Etavopivat A, Etavopivat B, Etavopivat C - Sickle Cell Disease, Thalassemia | Phase 3 | Recruiting | Novo Nordisk A/S | 480 | 2025-01-10 | 2026-09-18 |
| A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) Crizanlizumab, Placebo - Sickle Cell Disease | Phase 3 | Recruiting | Novartis Pharmaceuticals | 354 | 2024-10-24 | 2026-11-10 |
| Intranasal Sufentanil for Analgesia of Severe Sickle Cell Vaso-occlusive Pain Crisis in the Pediatric Sufentanil - Vaso-occlusive Crisis | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 182 | 2024-05-02 | 2023-12-26 |
| Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa Hydroxyurea - Sickle Cell Anemia in Children, Sickle Cell Disease | Phase 3 | Recruiting | Brown University | 400 | 2023-11-15 | 2026-08-20 |
Showing 20 of 150. Sign in to see all of them.
Anemia, Sickle Cell (108) · beta-Thalassemia (32) · Vaso-Occlusive Crises (26) · Hematologic Diseases (19) · Thalassemia (19) · Iron Overload (9) · Acute Chest Syndrome (7) · Genetic Diseases, Inborn (6) · Sickle Cell Trait (6) · Stroke (6) · Agnosia (5) · Anemia (5) · Pain (5) · Hypertension, Pulmonary (4)
Anemia, Hemolytic, Congenital (150) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (150) · Hemic and Lymphatic Diseases (150) · Anemia, Hemolytic (149) · Anemia (145) · Genetic Diseases, Inborn (144) · Hematologic Diseases (131) · Thalassemia (24) · Pathological Conditions, Signs and Symptoms (15) · Metabolic Diseases (14) · Nervous System Diseases (14) · Nutritional and Metabolic Diseases (14) · Respiratory Tract Diseases (14) · Lung Diseases (13)
Hydroxyurea (17) · Deferasirox (9) · exagamglogene autotemcel (7) · Deferoxamine (6) · Deferiprone (5) · voxelotor (5) · Blood Transfusion (4) · Docosahexaenoic Acids (4) · Morphine (4) · Thalidomide (4) · Amlodipine (3) · Bosentan (3) · Glutamine (3) · Isoflurophate (3) · Ketamine (3)
Pfizer (11) · Assistance Publique - Hôpitaux de Paris (8) · Ain Shams University (7) · Novartis Pharmaceuticals (7) · Vertex Pharmaceuticals Incorporated (7) · National Heart, Lung, and Blood Institute (NHLBI) (4) · Actelion (3) · Children's Hospital Medical Center, Cincinnati (3) · Genetix Biotherapeutics Inc. (3) · Indiana University (3) · Mast Therapeutics, Inc. (3) · Agios Pharmaceuticals, Inc. (2) · AstraZeneca (2) · Augusta University (2) · Beni-Suef University (2)
United States (66) · United Kingdom (31) · France (28) · Italy (28) · Egypt (24) · Canada (21) · Turkey (Türkiye) (20) · Brazil (19) · Germany (18) · Lebanon (18) · Oman (16) · Kenya (15) · Nigeria (15) · Saudi Arabia (15) · Belgium (13)
Michael R. DeBaun, MD, MPH (3) · Russell E. Ware, MD, PhD (3) · Ahmed F Mahmoud Hussein, MS.c (2) · Anders Berggren, MD, PhD (2) · Charles Quinn, MD (2) · Claudia Morris, MD (2) · Donald Brambilla (2)
PMID 37975597, PMID 37254256, PMID 20175775, PMID 19721013, PMID 30952488, PMID 33283989, PMID 34175041, PMID 35981565, PMID 38775255, PMID 40857358, PMID 40862696, PMID 42252696, PMID 42274009, PMID 16382063, PMID 17951527, PMID 18055982, PMID 18351337, PMID 18478575, PMID 19621454, PMID 19813252, PMID 19856395, PMID 19880138, PMID 19951979, PMID 19996412, PMID 20424435, PMID 20566896, PMID 20797449, PMID 21071497, PMID 21179892, PMID 21217080, PMID 21523806, PMID 21571150, PMID 21606305, PMID 21744485, PMID 21826782, PMID 21848879, PMID 22180427, PMID 22190441, PMID 22294512, PMID 22318199, PMID 22915643, PMID 23539110, PMID 23585526, PMID 23585527, PMID 23861242, PMID 23927461, PMID 23999955, PMID 24276838, PMID 24443249, PMID 24529619
2019 (4), 2023 (4), 2017 (2), 2004 (1), 2025 (1), K23HL136787 (1), N01HB07150 (1), N01HB07151 (1), N01HB07152 (1), N01HB07153 (1), N01HB07154 (1), N01HB07155 (1), N01HB07156 (1), N01HB07157 (1), N01HB07158 (1)